[go: up one dir, main page]

UY37271A - Composiciones nasales de cannabinoides - Google Patents

Composiciones nasales de cannabinoides

Info

Publication number
UY37271A
UY37271A UY0001037271A UY37271A UY37271A UY 37271 A UY37271 A UY 37271A UY 0001037271 A UY0001037271 A UY 0001037271A UY 37271 A UY37271 A UY 37271A UY 37271 A UY37271 A UY 37271A
Authority
UY
Uruguay
Prior art keywords
nasal
methods
pharmaceutical compositions
cannabinoid
cannabinoid compositions
Prior art date
Application number
UY0001037271A
Other languages
English (en)
Inventor
Nathan Bryson
Avinash Sharma
Original Assignee
Acerus Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60478110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerus Pharmaceuticals Corp filed Critical Acerus Pharmaceuticals Corp
Publication of UY37271A publication Critical patent/UY37271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición de cannabinoide semisólida o líquida viscosa administrada por vía nasal, métodos nasales para la administración de las composiciones farmacéuticas nasales, métodos para la fabricación de composiciones farmacéuticas nasales, y métodos nasales para el tratamiento de enfermedades tratables por medio de composiciones farmacéuticas nasales formuladas con un cannabinoide o mezclas de estas.
UY0001037271A 2016-06-02 2017-06-02 Composiciones nasales de cannabinoides UY37271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344486P 2016-06-02 2016-06-02
US201662426403P 2016-11-25 2016-11-25

Publications (1)

Publication Number Publication Date
UY37271A true UY37271A (es) 2017-11-30

Family

ID=60478110

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037271A UY37271A (es) 2016-06-02 2017-06-02 Composiciones nasales de cannabinoides

Country Status (12)

Country Link
US (1) US20170348276A1 (es)
EP (1) EP3478270A4 (es)
KR (1) KR102433459B1 (es)
CN (1) CN109789090A (es)
BR (1) BR112018075073A2 (es)
CA (1) CA3026274A1 (es)
CL (1) CL2018003452A1 (es)
CO (1) CO2018013654A2 (es)
MX (1) MX392668B (es)
TW (1) TWI790204B (es)
UY (1) UY37271A (es)
WO (1) WO2017208072A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
SI3687513T1 (sl) 2017-09-28 2022-04-29 Zynerba Pharmaceuticals, Inc. Zdravljenje sindroma fragilnega kromosoma X in avtizma s kanabidiolom
US20190240148A1 (en) * 2018-02-07 2019-08-08 Tarukino Holdings, Inc. Lubricant composition and method for preparing the composition
CA3092914A1 (en) * 2018-03-05 2019-09-12 Solva, Llc Water-soluble phytocannabinoid formulations
US11020357B2 (en) * 2018-03-19 2021-06-01 Alexandra Yerike Compound for use in relief of pain and method to produce thereof
EP3856172A4 (en) * 2018-09-28 2022-10-05 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
US20200170962A1 (en) * 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
WO2020142692A1 (en) * 2019-01-04 2020-07-09 Columbia Care Llc Topical formulations having cannabinoid
US20200215024A1 (en) * 2019-01-08 2020-07-09 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
BR112021014976A2 (pt) * 2019-02-08 2021-10-05 Schedule 1 Therapeutics, Inc. Composições compreendendo canabinoides e métodos de uso das mesmas
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US20220257560A1 (en) * 2019-05-23 2022-08-18 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of tourette syndrome
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
ES2986160T3 (es) 2019-08-30 2024-11-08 Evie Sa Gránulos cargados, su proceso de producción y sus usos
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
US11419800B2 (en) 2019-12-06 2022-08-23 JLABS Beauty LLC Topical compositions containing rose oil and cannabidiol and methods of making and using the same
TWI708835B (zh) * 2020-01-17 2020-11-01 和協工程股份有限公司 緩釋型釋碳凝膠基質及土壤整治方法
CH717205A1 (de) * 2020-03-11 2021-09-15 Jk Holding Gmbh Verwendung von Cannabinoiden in Therapie- und Wellnessgeräten.
US20210322343A1 (en) * 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
EP4164613A4 (en) * 2020-06-20 2024-10-23 Chavan, Neha COMPOSITIONS FOR SOLUBILISING WATER-INSOLUBLE ACTIVE SUBSTANCES
EP3984522A1 (de) * 2020-10-19 2022-04-20 Shima Khaki Zusammensetzung, vorrichtung und verwendung
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
IT202100014909A1 (it) * 2021-06-08 2022-12-08 Velleja Res S R L Formulazioni oleose di cannabinoidi
CN113304109A (zh) * 2021-06-08 2021-08-27 内蒙古大唐药业股份有限公司 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法
WO2023028708A1 (en) * 2021-09-02 2023-03-09 Canopy Growth Corporation Water-soluble cannabinoid compositions, methods of making and use
US11471905B1 (en) 2021-09-23 2022-10-18 Apackaging Group Llc All plastic airless pump dispenser
EP4186490A1 (en) 2021-11-29 2023-05-31 Sanity Group GmbH Kit for preparing a medicament, cannabinoid composition, and preparation method
GB2634400A (en) * 2022-03-15 2025-04-09 Milehigh Repro Solutions Llc Methods and systems to reduce injury in treated tissues
KR20250008060A (ko) 2022-04-12 2025-01-14 섀클포드 파마 인코포레이티드 발작 장애의 치료
WO2024010628A1 (en) * 2022-07-05 2024-01-11 Poviva Corp Pharmaceutical compositions and methods for treating hypertension
US11666543B1 (en) * 2022-07-05 2023-06-06 Poviva Corp. Pharmaceutical compositions and methods for treating hypertension
US11980593B2 (en) 2022-07-05 2024-05-14 Poviva Corp. Compositions and methods for treating hypertension
WO2025024007A1 (en) * 2023-07-24 2025-01-30 Poviva Corp . Compositions and methods for treating epilepsy
WO2025140869A1 (en) * 2023-12-28 2025-07-03 Linnea Sa Process for stabilising a macerated oil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
KR20240162608A (ko) * 2011-05-15 2024-11-15 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
WO2017208072A2 (en) 2017-12-07
EP3478270A4 (en) 2019-11-27
CN109789090A (zh) 2019-05-21
TWI790204B (zh) 2023-01-21
TW201801721A (zh) 2018-01-16
WO2017208072A3 (en) 2018-01-11
MX2018014978A (es) 2019-09-04
EP3478270A2 (en) 2019-05-08
CA3026274A1 (en) 2017-12-07
MX392668B (es) 2025-03-24
KR20190034506A (ko) 2019-04-02
BR112018075073A2 (pt) 2019-04-30
KR102433459B1 (ko) 2022-08-17
US20170348276A1 (en) 2017-12-07
CO2018013654A2 (es) 2019-08-30
CL2018003452A1 (es) 2019-06-21

Similar Documents

Publication Publication Date Title
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
MX385332B (es) Moduladores de ror-gamma.
CO2018002060A2 (es) Compuestos farmacéuticos
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2019013878A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
CO2019002245A2 (es) Combinación de agonistas de fxr
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20231226